Drug Database · Clinicians

Loperamide

Brands (42) Golmide, Abydium, Amblomide…Show all

US brand (reference label): Loperamide Hydrochloride; not a Philippine-registered brand.

Antimotility; Antipropulsive (antimotility); and others PH FDA category

Rx · Prescription drugOTC · Over-the-counter60 PH productsPNF-listed
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 03c907d5-87f8-47a6-9544-5a24f5272739, version date January 5, 2026 (Loperamide Hydrochloride · Advagen Pharma Ltd.,). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies.

Contraindications

CONTRAINDICATIONS Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter. patients with pseudomembranous colitis (e.g., Clostridium difficle) associated with the use of broad-spectrum antibiotics.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Loperamide hydrochloride capsules USP are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see CONTRAINDICATIONS). Avoid loperamide hydrochloride capsules dosages higher than recommended in adult or pediatric patients 2 years of age and older due to the risk of serious cardiac adverse reactions (see WARNINGS, OVERDOSAGE).

(1 capsule = 2 mg) Patients should receive appropriate fluid and electrolyte replacement as needed. Acute Diarrhea Adults and Pediatric Patients 13 Years and Older: The recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool. The maximum daily dose is 16 mg (eight capsules).

Clinical improvement is usually observed within 48 hours. Pediatric Patients 2 to 12 Years of Age: In pediatric patients 2 to 5 years of age (20 kg or less), the non-prescription liquid formulation of loperamide (1 mg/5 mL) should be used; for ages 6 to 12, either loperamide hydrochloride capsules or liquid formulation of loperamide may be used.

For pediatric patients 2 to 12 years of age, the following schedule for capsules or liquid will usually fulfill initial dosage requirements: Recommended First Day Dosage Schedule Two to five years (13 kg to 20 kg): 1 mg three times daily (3 mg total daily dosage) Six to eight years (20 kg to 30 kg): 2 mg twice daily (4 mg total daily dosage) Eight to twelve years (greater than 30 kg): 2 mg three times daily (6 mg total daily dosage) Recommended Subsequent Daily Dosage Following the first treatment day, it is recommended that subsequent loperamide hydrochloride capsules doses (1 mg/10 kg body weight) be administered only after a loose stool. Total daily dosage should not exceed recommended dosages for the first day.

Chronic Diarrhea Adults The recommended initial dose is 4 mg (two capsule) followed by 2 mg (one capsule) after each unformed stool until diarrhea is controlled, after which the dosage of loperamide hydrochloride capsules should be reduced to meet individual requirements. When the optimal daily dosage has been established, this amount may then be administered as a single dose or in divided doses.

The average daily maintenance dosage in clinical trials was 4 mg to 8 mg (two to four capsules per day). The maximum daily dosage is 16 mg (eight capsules per day). If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration.

Loperamide hydrochloride capsules administration may be continued if diarrhea cannot be adequately controlled with diet or specific treatment. Elderly No formal pharmacokinetic studies were conducted in elderly subjects. However, there were no major differences reported in the drug disposition in elderly patients with diarrhea relative to young patients.

No dose adjustment is required for the elderly. In general, elderly patients may be more susceptible to drug-associated effects of the QT interval. Avoid loperamide hydrochloride capsules in elderly patients taking drugs that can result in prolongation of the QT interval (for example, Class IA or III antiarrhythmics) or in patients with risk factors for Torsades de Pointes (see WARNINGS).

Renal Impairment No pharmacokinetic data are available in patients with renal impairment. Since the metabolites and the unchanged drug are mainly excreted in the feces, no dosage adjustment is required for patients with renal impairment (see PRECAUTIONS). Hepatic Impairment The pharmacokinetics of loperamide have not been studied in patients with hepatic impairment.

Use loperamide hydrochloride capsules with caution in such patients because the systemic exposure may be increased due to reduced metabolism (see PRECAUTIONS).

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

Renal Impairment No pharmacokinetic data are available in patients with renal impairment. Since the metabolites and the unchanged drug are mainly excreted in the feces, no dosage adjustment is required for patients with renal impairment (see PRECAUTIONS).

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see CONTRAINDICATIONS). Postmarketing cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients less than 2 years of age (see WARNINGS).

Pediatric patients may be more sensitive to CNS effects, such as altered mental status, somnolence, and respiratory depression, than adults. There have been rare reports of paralytic ileus associated with abdominal distention. Most of these reports occurred in the setting of acute dysentery, overdose, and with pediatric patients less than two years of age.

Loperamide hydrochloride capsules should be used with special caution in pediatric patients because of their greater variability of response (see WARNINGS). Dehydration, particularly in pediatric patients less than 6 years of age, may further influence the variability of response to loperamide hydrochloride capsules. The safety and effectiveness of loperamide hydrochloride capsules in pediatric patients with chronic diarrhea have not been established.

Although loperamide hydrochloride capsules have been studied in a limited number of pediatric patients with chronic diarrhea; the therapeutic dose for the treatment of chronic diarrhea in a pediatric population has not been established. In case of accidental overdosage of loperamide hydrochloride capsules by pediatric patients, see OVERDOSAGE for suggested treatment.

Dosage forms

Philippines

  • Capsule: 2 mg, 10 mg
  • Tablet: 2 mg

Registered products in the Philippines

60 products registered with the Food and Drug Administration (FDA) Philippines list Loperamide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products60
Philippine FDA-registered products for Loperamide
Package insert
AbydiumLoperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-14645
Apr 21, 2031
AmblomideLoperamide
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Kanion Pharmaceutical Co., Ltd.China
AMB HK Enterprises, Inc.
DRP-10304
Sep 8, 2031
ByerrheaLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Brawn Laboratories LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5130-01
Feb 13, 2029
DatabLoperamide Hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of and 30's); PVC Blister Pack x 10's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-4358
Apr 3, 2028
DiacureLoperamide Hydrochloride
2 mg CapsuleAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-9045
Aug 7, 2030
DiakhrizLoperamide
2 mg Capsule
OTC
Merit Organics Ltd.India
Khriz Pharma Trading Inc
DRP-17733
Feb 24, 2031
DialomideLoperamide Hydrochloride
2 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
Diamond Laboratories Inc.Philippines
—
DRP-7212
Feb 12, 2032
DiamideLoperamide HCl
2 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's)
OTC
Phil. United Pharma CorporationPhilippines
ATC HEALTHCARE INTERNATIONAL CORPORATION
DRP-11216
Feb 15, 2027
DiarelLoperamide hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Zee LaboratoriesIndia
Importer: EON PHARMATEK INC
DR-XY47138
Dec 28, 2030
DiasolvLoperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-9365
Mar 2, 2029
DiastopLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
OTC
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-1886
Sep 13, 2029
DiatabsLoperamide Hydrochloride
2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's); Aluminum Foil Strip x 4's (Box of 500's); Aluminum Foil Strip x 4's (Envelope of 1's)
OTC
UNILAB, Inc.Philippines
—
DR-XY24964
Mar 15, 2029
DocmideLoperamide Hydrochloride
2 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's)
OTC
Phil. United Pharma CorporationCavite
Trader: Docteur's Choice Corporation
DRP-10206
Aug 6, 2031
GolmideLoperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's, 30's, and 100's); Alu/PVC Blister Pack x 10's Box of 30's; Alu/PVC Blister Pack x 10's Box of 100's
OTC
Phil. United Pharma CorporationCavite
Trader: Golden Dale Pharma Corp.
DRP-10339
Sep 14, 2031
GolmideLoperamide Hydrochloride
2 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, and 100's)
OTC
Phil. United Pharma Corp.Philippines
Golden Dale Pharma Corp.
DRP-13298
Jan 19, 2028
GoperamideLoperamide
2mg CapsuleAlu-PVC Blister Pack of 10's (Box of 100's)
OTC
Ratnatris Pharmaceuticals Pvt. Ltd.India
Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc
DRP-12190-01
Jun 28, 2027
GopramideLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Brawn Laboratories LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation
DRP-5130-02
Feb 13, 2029
HarvimideLoperamide (as hydrochloride)
2 mg CapsuleBlister Pack x 10's (Box of 100's)
OTC
Scheele Laboratories Phils., IncPhilippines
—
DR-XY22591-B
Mar 21, 2031
ImodiumLoperamide hydrochloride
2 mg CapsuleBlister Pack x 2's (Box of 4's); Blister Pack x 10's (Box of 10's); Blister Pack x 10's (Box of 200's)
OTC
Interphil Laboratories, Inc.Philippines
Johnson & Johnson (Philippines), Inc
DR-XY14916
Jul 7, 2028
ImotabLoperamide hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-4378
Mar 18, 2028
KoramideLoperamide hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Konzept Convenience and Drug Store Corp.
DRP-4378-06
Mar 18, 2028
LomotilLoperamide Hydrochloride
2 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Interphil Laboratories, IncPhilippines
JNTL Consumer Health (Philippines) Inc.
DR-XY27914
Mar 10, 2031
LoniperLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Foramen Products Corporation
DRP-297
Oct 8, 2030
LopediumLoperamide Hydrochloride
2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's)
OTC
Ratnatris Pharmaceuticals Private LimitedIndia
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12190-02
Jun 28, 2027
LopegenLoperamide Hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-4378-01
Mar 18, 2028
LopelifeLoperamide Hydrochloride
2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's)
OTC
Ratnatris Pharmaceuticals Private LimitedIndia
Life And Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc.
DRP-12190-04
Jun 28, 2027
LopemidLoperamide hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-4378-03
Mar 18, 2028
LoperaCapLoperamide Hydrochloride
2mg CapsulePVC-Alu Blister Pack x 10’s (Box of 10’s); PVC-Alu Blister Pack x 10’s (Box of 30’s)
OTC
Phil. United Pharma CorporationPhilippines
ATC HEALTHCARE INTERNATIONAL CORP.
DR-XY46224
Jan 24, 2028
LoperamedLoperamide Hydrochloride
2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's)
OTC
Ratnamani Healthcare Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-12190
Jun 28, 2027
LoperazanLoperamide Hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of and 30's and 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical And Pharma Inc.
DRP-4358-01
Apr 3, 2028
LopranLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-5130
Feb 13, 2029
LorbanLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 100's
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Inc.
DR-XY25228
May 25, 2029
MonclomideLoperamide
2 mg CapsuleBlister Pack x 10's (Box of 100's)
OTC
Scheele Laboratories Phils., Inc.Philippines
999 Seth Pharmaceutical Inc.
DRP-164-02
Feb 25, 2027
MotilesLoperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY46603
Jun 4, 2029
MotirexLoperamide Hydrochloride
2 mg CapsuleClear PVC/Alu Blister Pack x 20's (Box of 100's)
OTC
New Myrex Laboratories, Inc.Philippines
—
DR-XY38945
Jan 13, 2030
NodiaLoperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY46607
Jun 4, 2029
NoneLoperamide Hydrochloride
2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's)
OTC
Interphil Laboratories, Inc.Philippines
Icon Healthcare, Inc.
DRP-1911-02
Jun 3, 2031
NoneLoperamide Hydrochloride
2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's)
OTC
Interphil Laboratories, Inc.Philippines
South Star Drug
DRP-1911-03
Aug 10, 2031
NoneLoperamide hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
BEWISE TRADING CORP. Doing business under the name & style of PHARMAPLUS GENERIC & BRANDED DRUG DISTRIBUTOR & MEDICAL SUPPLIES
DRP-4378-07
Mar 18, 2028
NoneLoperamide Hydrochloride
2 mg CapsuleBlister pack x 20's (Box of 100's)
Rx
Drugmaker's Laboratories Inc.Philippines
—
DRP-5554
Aug 3, 2030
NoneLoperamide Hydrochloride
2 mg CapsuleBlister Pack x 10's (Box of 100's); Blister Foil x 10's (Envelope Pack); Blister Pack x 10's (Box of 10's)
Rx
Am-Europharma CorporationPhilippines
Personal Collection Direct Selling, Inc.
DRP-562
Oct 10, 2031
NoneLoperamide Hydrochloride
2 mg CapsuleBlister Pack x 10's (Box of 100's)
OTC
Am-Europharma CorporationPhilippines
Onesource Pharma Solutions, Inc.
DRP-562-05
Jul 30, 2031
NoneLoperamide
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-7091
May 22, 2029
NoneLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Dr. Zen’s Research, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-7091-02
May 22, 2029
NoneLoperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceuticals, Inc.
DRP-9365-01
Mar 2, 2029
NoneLoperamide Hydrochloride
2mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Eurasia Research Pharma CorporationPhilippines
—
DR-XY45225
Apr 1, 2031
RamideLoperamide hydrochloride
2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-4378-04
Mar 18, 2028
RetamideLoperamide Hydrochloride
2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's)
OTC
Ratnatris Pharmaceuticals Private LimitedIndia
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-12190-03
Jun 28, 2027
RexamideLoperamide
10 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Next Wave (India)India
Aarex Pharma Distributor
DRP-12314
Jul 13, 2027
SpasmobanLoperamide Hydrochloride
2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's); , Aluminum Foil Strip x 2's (Physician's Sample)
OTC
Interphil Laboratories, Inc.Philippines
—
DRP-1911
Mar 15, 2031
TGP-LoperLoperamide Hydrochloride
2 mg CapsuleClear PVC/Alu Blister Pack x 20's (Box of 100's)
Rx
New Myrex Laboratories, Inc.Philippines
TGP Pharma Inc.
DR-XY38833
Dec 8, 2030
UnbrandedLoperamide Hydrochloride
2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's)
OTC
Interphil Laboratories, Inc.Philippines
Rose Pharmacy, Incorporated
DRP-1911-01
Jun 17, 2031
UnbrandedLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Gamot Philippines, Inc.Trader: Foramen Products Corporation
DRP-297-04
Aug 6, 2031
UnbrandedLoperamide Hydrochloride
2 mg CapsuleBlister Pack x 10's (Box of 100's)
OTC
AM-Europharma CorporationPhilippines
RITEMED PHILS., INC.
DRP-562-01
Oct 30, 2031
UnbrandedLoperamide Hydrochloride
2 mg TabletAlu/Red PVC Blister Pack X 25's (Box of 100's)
Rx
Vonwelt Inc.Philippines
—
DRP-7806
Nov 14, 2031
UnbrandedLoperamide
Tablet 2 mgAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
—
DRP-9686
May 5, 2031
United Home LormideLoperamide Hydrochloride
2 mg CapsuleAluminum Foil Strip Pack x 4's (Box of 100's)
OTC
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-X6084
May 24, 2027
VexilLoperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
OTC
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-8679
Aug 24, 2031
(no brand name)Loperamide Hydrochloride
2 mg CapsuleAlu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Vonwelt Inc.Philippines
—
DRP-13569
Jul 22, 2029
(no brand name)Loperamide Hydrochloride
2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Scheele Laboratories Phils., Inc.Philippines
—
DRP-17043
Sep 12, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS Cardiac Adverse Reactions, Including Torsades de Pointes and Sudden Death Cases of prolongation of the QT/QTc interval, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, some resulting in death, have been reported in adults with use of higher than recommended doses per day of loperamide hydrochloride capsules. Cases include patients who were abusing or misusing loperamide hydrochloride (see OVERDOSAGE and DRUG ABUSE AND DEPENDENCE).

Cases of syncope and ventricular tachycardia have been reported in adult patients receiving the recommended dosage of loperamide hydrochloride capsules. Some of these patients were taking other drugs or had other risk factors that may have increased their risk of cardiac adverse reactions. Additionally, postmarketing cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients less than 2 years of age.

Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions. Avoid loperamide hydrochloride capsules dosages higher than recommended in adults and pediatric patients 2 years of age and older due to the risk of serious cardiac adverse reactions (see DOSAGE AND ADMINISTRATION and OVERDOSAGE).

Avoid loperamide hydrochloride capsules in: combination with others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval (e.g., pentamidine, levomethadyl acetate, methadone). patients with risk factors for QT prolongation, including patients with congenital long QT syndrome, with a history of cardiac arrhythmias or other cardiac conditions, elderly patients and those with electrolyte abnormalities. Dehydration Fluid and electrolyte depletion often occur in patients who have diarrhea.

In such cases, administration of appropriate fluid and electrolytes is very important. The use of loperamide hydrochloride capsules does not preclude the need for appropriate fluid and electrolyte therapy. Gastrointestinal Disorders In general, loperamide hydrochloride capsules should not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon.

Loperamide hydrochloride capsules must be discontinued promptly when constipation, abdominal distention or ileus develop. Treatment of diarrhea with loperamide hydrochloride capsules is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate (or when indicated).

Patients with AIDS treated with loperamide hydrochloride capsules for diarrhea should have therapy stopped at the earliest signs of abdominal distention. There have been isolated reports of toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide hydrochloride.

Variability in Pediatric Response Loperamide hydrochloride capsules should be used with special caution in pediatric patients because of the greater variability of response in this age group. Dehydration, particularly in pediatric patients less than 6 years of age, may further influence the variability of response to loperamide hydrochloride capsules.

Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. The increased systemic exposure to loperamide may increase a risk for cardiac adverse reactions especially in patients who are taking multiple CYP enzyme inhibitors, or in patients with underlying cardiac conditions (see WARNINGS).

Monitor patients for cardiac adverse reactions. CYP3A4 Inhibitors Itraconazole Concomitant administration of multiple doses of 100 mg itraconazole twice daily, an inhibitor of both CYP3A4 and P-glycoprotein, with a single 4 mg dose of loperamide hydrochloride increased the peak plasma concentration and the systemic exposure to loperamide by 2.9-fold and 3.8-fold, respectively.

CYP2C8 Inhibitors Gemfibrozil When a single 4 mg dose of loperamide hydrochloride was coadministered with 600 mg gemfibrozil, a strong inhibitor of CYP2C8, on day 3 of a 5-day treatment with gemfibrozil twice daily, the mean peak plasma concentration and the systemic exposure to loperamide was increased by 1.6-fold and 2.2-fold, respectively. CYP3A4 and CYP2C8 Inhibitors When multiple doses of both 100 mg itraconazole and 600 mg gemfibrozil twice daily were administered with a single 4 mg dose of loperamide hydrochloride, the mean peak plasma concentration and the systemic exposure to loperamide was increased by 4.2-fold and 12.6-fold, respectively.

P-glycoprotein Inhibitors Concomitant administration of a 16 mg single dose of loperamide hydrochloride with a 600 mg single dose of quinidine or ritonavir, both of which are P-glycoprotein inhibitors, resulted in a 2- to 3-fold increase in loperamide plasma concentrations. Due to the potential for enhanced CNS adverse reactions when loperamide is coadministered with quinidine and with ritonavir, caution should be exercised when loperamide hydrochloride capsules are administered at the recommended dosages (2 mg, up to 16 mg maximum daily dose) with P-glycoprotein inhibitors.

Effects of Loperamide on Other Drugs Saquinavir When a single 16 mg dose of loperamide hydrochloride is coadministered with a 600 mg single dose of saquinavir, loperamide decreased saquinavir exposure by 54%, which may be of clinical relevance due to reduction of therapeutic efficacy of saquinavir. The effect of saquinavir on loperamide is of less clinical significance.

Therefore, when loperamide hydrochloride capsules are given with saquinavir, the therapeutic efficacy of saquinavir should be closely monitored. Carcinogenesis, Mutagenesis, Impairment of Fertility In an 18-month rat study with oral loperamide hydrochloride doses up to 40 mg/kg/day (21 times the maximum human dose of 16 mg/day, based on a body surface area comparison), there was no evidence of carcinogenesis.

Loperamide was not genotoxic in the Ames test, the SOS chromotest in E. coli, the dominant lethal test in female mice, or the mouse embryo cell transformation assay. Fertility and reproductive performance was evaluated in rats using oral doses of 2.5 mg/kg/day, 10 mg/kg/day, and 40 mg/kg/day (females only) in a second study.

Oral administration of 20 mg/kg/day (approximately 11 times the human dose based on a body surface area comparison) and higher, produced a strong impairment of female fertility. Treatment of female rats with up to 10 mg/kg/day (approximately 5 times the human dose based on a body surface area comparison) had no effect on fertility.

Treatment of male rats with oral doses of 40 mg/kg/day (approximately 21 times the human dose based on a body surface area comparison) produced impairment of male fertility, whereas administration of up to 10 mg/kg/day (approximately 5 times the human dose based on a body surface area comparison) had no effect.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Loperamide is a P-glycoprotein substrate.

Metabolism In vitro loperamide is metabolized mainly by cytochrome P450 (CYP450) isozymes, CYP2C8 and CYP3A4, to form- N-demethyl loperamide.

In an in vitro study, quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) significantly inhibited the N-demethylation process by 40% and 90%, respectively.

In addition, CYP2B6 and CYP2D6 appear to play a minor role in loperamide N- demethylation.

Concomitant use of loperamide hydrochloride with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide (see PRECAUTIONS : Drug Interactions ).

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide.

CYP3A4 Inhibitors Itraconazole Concomitant administration of multiple doses of 100 mg itraconazole twice daily, an inhibitor of both CYP3A4 and P-glycoprotein, with a single 4 mg dose of loperamide hydrochloride increased the peak plasma concentration and the systemic exposure to loperamide by 2.9-fold and 3.8-fold, respectively.

CYP2C8 Inhibitors Gemfibrozil When a single 4 mg dose of loperamide hydrochloride was coadministered with 600 mg gemfibrozil, a strong inhibitor of CYP2C8, on day 3 of a 5-day treatment with gemfibrozil twice daily, the mean peak plasma concentration and the systemic exposure to loperamide was increased by 1.6-fold and 2.2-fold, respectively.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Clinical Trial Experience The adverse effects reported during clinical investigations of loperamide hydrochloride capsules are difficult to distinguish from symptoms associated with the diarrheal syndrome. Adverse experiences recorded during clinical studies with loperamide hydrochloride capsules were generally of a minor and self-limiting nature.

They were more commonly observed during the treatment of chronic diarrhea. The adverse events reported are summarized irrespective of the causality assessment of the investigators. 1) Adverse events from 4 placebo-controlled studies in patients with acute diarrhea The adverse events with an incidence of 1.0% or greater, which were reported at least as often in patients on loperamide hydrochloride as on placebo, are presented in the table below.

Acute Diarrhea Loperamide Hydrochloride Placebo No. of treated patients 231 236 Gastrointestinal AE% Constipation 2.6% 0.8% The adverse events with an incidence of 1.0% or greater, which were more frequently reported in patients on placebo than on loperamide hydrochloride, were: dry mouth, flatulence, abdominal cramp and colic. 2) Adverse events from 20 placebo-controlled studies in patients with chronic diarrhea The adverse events with an incidence of 1.0% or greater, which were reported at least as often in patients on loperamide hydrochloride as on placebo, are presented in the table below. Chronic Diarrhea Loperamide Hydrochloride Placebo No. of treated patients 285 277 Gastrointestinal AE% Constipation 5.3% 0.0% Central and peripheral nervous system AE% Dizziness 1.4% 0.7% The adverse events with an incidence of 1.0% or greater, which were more frequently reported in patients on placebo than on loperamide hydrochloride were: nausea, vomiting, headache, meteorism, abdominal pain, abdominal cramp and colic. 3) Adverse events from 76 controlled and uncontrolled studies in patients with acute or chronic diarrhea The adverse events with an incidence of 1.0% or greater in patients from all studies are given in the table below.

Acute Diarrhea Chronic Diarrhea All Studies a No. of treated patients 1913 1371 3740 Gastrointestinal AE% Nausea 0.7% 3.2% 1.8% Constipation 1.6% 1.9% 1.7% Abdominal cramps 0.5% 3.0% 1.4% All patients in all studies, including those in which it was not specified if the adverse events occurred in patients with acute or chronic diarrhea. Postmarketing Experience The following adverse events have been reported: Cardiac Disorders QT/QTc-interval prolongation, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, syncope, and death (see WARNINGS and OVERDOSAGE).

Skin and Subcutaneous Tissue Disorders Rash, pruritus, urticaria, angioedema, and extremely rare cases of bullous eruption including erythema multiforme, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis have been reported with use of loperamide hydrochloride capsules. Immune System Disorders Isolated occurrences of allergic reactions and in some cases severe hypersensitivity reactions including anaphylactic shock and anaphylactoid reactions have been reported with the use of loperamide hydrochloride capsules.

Gastrointestinal Disorders Dry mouth, abdominal pain, distention or discomfort, nausea, vomiting, flatulence, dyspepsia, constipation, paralytic ileus, megacolon; including toxic megacolon (see CONTRAINDICATIONS, WARNINGS). Renal and Urinary Disorders Urinary retention Nervous System Disorders Drowsiness, dizziness General Disorders and Administrative Site Conditions Tiredness A number of the adverse events reported during the clinical investigations and postmarketing experience with loperamide are frequent symptoms of the underlying diarrheal syndrome (abdominal pain/discomfort, nausea, vomiting, dry mouth, tiredness, drowsiness, dizziness, constipation, and flatulence).

These symptoms are often difficult to distinguish from undesirable drug effects.

Adverse reaction frequency tables (US label) US FDA label
Acute Diarrhea
Loperamide HydrochloridePlacebo
No. of treated patients231236
Gastrointestinal AE% Constipation 2.6%0.8%
Chronic Diarrhea
Loperamide HydrochloridePlacebo
No. of treated patients285277
Gastrointestinal AE% Constipation 5.3%0.0%
Central and peripheral nervous system AE% Dizziness 1.4%0.7%
Acute DiarrheaChronic DiarrheaAll Studies a
No. of treated patients191313713740
Gastrointestinal AE% Nausea 0.7%3.2%1.8%
Constipation1.6%1.9%1.7%
Abdominal cramps0.5%3.0%1.4%

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects. Teratology studies have been performed in rats using oral loperamide hydrochloride doses of 2.5 mg/kg/day, 10 mg/kg/day, and 40 mg/kg/day, and in rabbits using oral doses of 5 mg/kg/day, 20 mg/kg/day, and 40 mg/kg/day. These studies have revealed no evidence of impaired fertility or harm to the fetus at doses up to 10 mg/kg/day in rats (5 times the human dose based on body surface area comparison) and 40 mg/kg/day in rabbits (43 times the human dose based on body surface area comparison).

Treatment of rats with oral doses of 40 mg/kg/day (21 times the human dose based on a body surface area comparison) produced marked impairment of fertility. The studies produced no evidence of teratogenic activity. There are no adequate and well controlled studies in pregnant women. Loperamide hydrochloride capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Non-Teratogenic Effects In a peri- and post-natal development study in rats, oral administration of 40 mg/kg/day produced impairment of growth and survival of offspring.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Small amounts of loperamide may appear in human breast milk. Therefore, loperamide hydrochloride capsules are not recommended during breast-feeding.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The apparent elimination half-life of loperamide is 10.8 hours with a range of 9.1 to 14.4 hours.

Excretion Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Mechanism of Action In vitro and animal studies show that loperamide hydrochloride capsules act by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing propulsive peristalsis, and increasing intestinal transit time.

Loperamide increases the tone of the anal sphincter, thereby reducing incontinence and urgency. Pharmacodynamics Loperamide prolongs the transit time of the intestinal contents. It reduces daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed.

Pharmacokinetics Absorption Plasma concentrations of unchanged drug remain below 2 ng/mL after the intake of a 2 mg capsule of loperamide hydrochloride. Plasma loperamide concentrations are highest approximately 5 hours after administration of the capsule and 2.5 hours after the liquid. The peak plasma concentrations of loperamide were similar for both formulations.

Distribution Based on literature information, the plasma protein binding of loperamide is about 95%. Loperamide is a P-glycoprotein substrate. Elimination The apparent elimination half-life of loperamide is 10.8 hours with a range of 9.1 to 14.4 hours. Elimination of loperamide mainly occurs by oxidative N-demethylation. Metabolism In vitro loperamide is metabolized mainly by cytochrome P450 (CYP450) isozymes, CYP2C8 and CYP3A4, to form- N-demethyl loperamide.

In an in vitro study, quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) significantly inhibited the N-demethylation process by 40% and 90%, respectively. In addition, CYP2B6 and CYP2D6 appear to play a minor role in loperamide N- demethylation. Concomitant use of loperamide hydrochloride with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide (see PRECAUTIONS: Drug Interactions).

Excretion Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Loperamide Hydrochloride 2 mg Capsule₱0.45–₱3.00Reference ₱0.92per capsuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Loperamide (as hydrochloride)
PNF listingOral: 2 mg capsule (N.B.: Not for infants and children less than 12 years old)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Loperamide Hydrochloride · Advagen Pharma Ltd., [US FDA-approved label, version 3, January 5, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c907d5-87f8-47a6-9544-5a24f5272739
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .